REA in 1VIT15043 Study

A randomized, double-blind, placebo controlled study to investigate the efficacy and safety of injectafer (ferric carboxymaltose as therapy for patient with heart failure and iron deficiency.

Awarded By

  • Luitpold Pharmaceuticals

Contributors

Amount

  • $28,687,822.00

Start/End

  • 2017 - 2020